Dulaglutide decreases liver enzymes in people with type 2 diabetes: a post-hoc analysis of the AWARD programme

被引：0
|
作者：
Haupt, A. [1 ]
Cusi, K. [2 ]
Sattar, N. [3 ]
Garcia-Perez, L. -E. [1 ]
Pavo, I. [4 ]
Yu, M. [5 ]
Robertson, K. E. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Florida, Dept Med, Div Endocrinol Diabet & Metab, Gainesville, FL USA
[3] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[4] Eli Lilly & Co, Vienna, Austria
[5] Eli Lilly & Co, Toronto, ON, Canada
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1248
引用
收藏
页码：S574 / S575
页数：2
相关论文
共 50 条
  • [1] Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
    Cusi, K.
    Sattar, N.
    Garcia-Perez, L. -E.
    Pavo, I.
    Yu, M.
    Robertson, K. E.
    Karanikas, C. A.
    Haupt, A.
    [J]. DIABETIC MEDICINE, 2018, 35 (10) : 1434 - 1439
  • [2] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif
    Sutherland, Sindee
    Karanikas, Chrisanthi A.
    Konig, Manige
    [J]. DIABETES THERAPY, 2019, 10 (06) : 2321 - 2330
  • [3] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Hiren Patel
    Kashif Munir
    Sindee Sutherland
    Chrisanthi A. Karanikas
    Manige Konig
    [J]. Diabetes Therapy, 2019, 10 : 2321 - 2330
  • [4] Changes in Lipid Concentrations in Patients with Type 2 Diabetes on Once-Weekly Dulaglutide 1.5 mg: Post-hoc Pooled Analysis of the AWARD Trials
    Sattar, Naveed A.
    Garcia-Perez, Luis E.
    Tao, Yebin
    Thieu, Vivian T.
    Pavo, Imre
    [J]. DIABETES, 2017, 66 : A288 - A289
  • [5] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Qifu Li
    Qiqi Zhang
    Rui Wang
    Tianpei Hong
    [J]. Diabetes Therapy, 2022, 13 : 161 - 173
  • [6] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Li, Qifu
    Zhang, Qiqi
    Wang, Rui
    Hong, Tianpei
    [J]. DIABETES THERAPY, 2022, 13 (01) : 161 - 173
  • [7] Dulaglutide treatment reduces glycaemic excursions in people with type 2 diabetes: a post-hoc analysis of 6 phase 3 randomised clinical trials
    Pechtner, V.
    Charpentier, G.
    Garcia-Perez, L. -E.
    Thieu, V. T.
    Jia, N.
    Jacobson, J. G.
    [J]. DIABETOLOGIA, 2017, 60 : S386 - S386
  • [8] Dulaglutide Treatment Reduces Glycemic Excursions in People with Type 2 Diabetes: A Post-hoc Analysis of Six Phase 3 Randomized Clinical Trials
    Charpentier, Guillaume
    Garcia-Perez, Luis E.
    Thieu, Vivian T.
    Jia, Nan
    Jacobson, Jennie G.
    Pechtner, Valeria
    [J]. DIABETES, 2017, 66 : A623 - A623
  • [9] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Gallo, Silvina
    Calle, Roberto A.
    Terra, Steven G.
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    [J]. DIABETES THERAPY, 2020, 11 (08) : 1849 - 1860
  • [10] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Silvina Gallo
    Roberto A. Calle
    Steven G. Terra
    Annpey Pong
    Lisa Tarasenko
    Annaswamy Raji
    [J]. Diabetes Therapy, 2020, 11 : 1849 - 1860
12345